TGFB1 and hepatocellular carcinoma: Although we cannot exclude the possibility that TGF-β could have been responsible for the acquisition of a mesenchymal phenotype and stem-related characteristics in early phases of HCC in these patients [8] and that in some cases galunisertib could reverse these changes, as we previously described [31], our work reveals that in some patients these changes could be irreversible, probably due to epigenetic alterations [32] or microenvironment characteristics [33].